Shire's $30B gambit, Merck's '100% effective' Ebola vaccine, and GSK's latest corruption scandal

Fierce editors discuss Shire's $30 billion bid for the nascent Baxalta, the promise of Merck's vaccine for Ebola, and the latest corruption allegations against GlaxoSmithKline.